CVE:PASPascal Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pascal Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.12 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.11Now: C$0.12▼C$0.1250-Day RangeC$0.08MA: C$0.10▼C$0.1352-Week RangeC$0.07Now: C$0.12▼C$0.20Volume65,122 shsAverage Volume77,212 shsMarket CapitalizationC$6.77 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesSocial Media Pascal Biosciences Inc., a drug discovery and development company, researches and develops biotechnology products for the treatment of cancer and for the enhancement of immune system in Canada. Its research programs include the development of Anti-VpreB, a therapeutic monoclonal antibody for treatment of B-cell precursor acute lymphoblastic leukemia in collaboration with the University of New Mexico; optimization of novel classes of molecules that restore immune recognition and killing of cancer cells; and regulating activity of immune system calcium channels to combat cancers, infections, and autoimmune diseases. The company has a collaboration agreement with the University of British Columbia. Pascal Biosciences Inc. is headquartered in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Pascal Biosciences. Previous Next 2.8 Community Rank Outperform VotesPascal Biosciences has received 55 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPascal Biosciences has received 42 “underperform” votes. (Add your “underperform” vote.)Community SentimentPascal Biosciences has received 56.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pascal Biosciences and other stocks. Vote “Outperform” if you believe PAS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PAS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPascal Biosciences does not currently pay a dividend.Dividend GrowthPascal Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pascal Biosciences insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pascal Biosciences is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pascal Biosciences is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:PAS Previous Symbol CUSIPN/A CIKN/A Webwww.biommune.net Phone+1-604-6886775Debt Debt-to-Equity RatioN/A Current Ratio0.37 Quick Ratio0.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.01 per share Price / Cash Flow19.17 Book ValueC$0.00 per share Price / Book-40.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees4 Outstanding Shares56,440,900Market CapC$6.77 million Next Earnings DateN/A OptionableNot Optionable TSXV:PAS Rates by TradingView Receive PAS News and Ratings via Email Sign-up to receive the latest news and ratings for PAS and its competitors with MarketBeat's FREE daily newsletter. Pascal Biosciences (CVE:PAS) Frequently Asked Questions How has Pascal Biosciences' stock been impacted by COVID-19 (Coronavirus)? Pascal Biosciences' stock was trading at C$0.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PAS stock has increased by 20.0% and is now trading at C$0.12. View which stocks have been most impacted by Coronavirus. Has Pascal Biosciences been receiving favorable news coverage? News stories about PAS stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pascal Biosciences earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutPascal Biosciences. Who are some of Pascal Biosciences' key competitors? Some companies that are related to Pascal Biosciences include Kazia Therapeutics (KZA), NovaBay Pharmaceuticals (NBY), Biocardia (BCDA), Nuformix (NFX), Noxopharm (NOX), Prana Biotechnology (PBT), Scancell (SCLP), Hemogenyx Pharmaceuticals (HEMO), Armata Pharmaceuticals (ARMP), Bio-Gene Technology (BGT), Fusion Antibodies (FAB), NovaBay Pharmaceuticals (NBY), Oragenics (OGEN), Bionomics (BNO) and Galena Biopharma (SLS). View all competitors. What other stocks do shareholders of Pascal Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pascal Biosciences investors own include Aurora Cannabis (ACB), Bonavista Energy (BNP), Bausch Health Companies (BHC), Axcella Health (AXLA), Abattis Bioceuticals (ATT), Athabasca Oil (ATH), Algonquin Power & Utilities (AQN), Aptinyx (APTX), Aphria (APHA) and Abacus Mining and Exploration (AME). Who are Pascal Biosciences' key executives? Pascal Biosciences' management team includes the following people: Dr. Patrick W. Gray, CEO & Director (Age 67)Ms. Judith F. Dalling L.L.B., CFO & Corp. Sec. (Age 64)Mr. Carl Weissman, Acting Pres (Age 57) What is Pascal Biosciences' stock symbol? Pascal Biosciences trades on the Canadian Venture Exchange (CVE) under the ticker symbol "PAS." How do I buy shares of Pascal Biosciences? Shares of PAS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Pascal Biosciences' stock price today? One share of PAS stock can currently be purchased for approximately C$0.12. How big of a company is Pascal Biosciences? Pascal Biosciences has a market capitalization of C$6.77 million. Pascal Biosciences employs 4 workers across the globe. What is Pascal Biosciences' official website? The official website for Pascal Biosciences is www.biommune.net. How can I contact Pascal Biosciences? Pascal Biosciences' mailing address is 400 Burrard St Suite 1780, VANCOUVER, BC V6C 3A6, Canada. The company can be reached via phone at +1-604-6886775. This page was last updated on 5/31/2020 by MarketBeat.com Staff
